Apyx Medical Corporation APYX Surgical Aesthetics — Investment Income Interest

Similar metrics at other companies

BLCOSurgical — Operating Income (Loss)

$9M+229%

IAR

IARTSpecialty Surgery — Operating Income (Loss)

$83.13M+15.1%

BLCOSurgical — Total revenues

$228M+6.5%

SGRYSurgical Facilities — Income (loss) before income taxes

-$3.3M-1,000%

FLGTLaboratory Services — Investment Income Interest

$8.65M+7.9%

DDSConstruction — Investment Income Interest

$220K+4.8%

Other financials

Income statement

See full

Revenue$12.5M+32.4%

Gross profit$7.5M-19.2%

Operating income-$5.5M-349%

Net income-$2.1M+48.6%

EPS (diluted)-$0.19-533%

Balance sheet

See full

Cash & equivalents$31.1M+0.4%

Total debt$39.5M+1.4%

Total equity$12.8M+22.1%

Total assets$63.0M+4.8%

Cash flow

See full

Operating cash flow-$572.0K+18.5%

CapEx$60.0K+9.1%

Free cash flow-$632.0K+16.5%

Valuation

See full

Market cap$181.07M+114%

Enterprise value$189.4M+101%

P/S3.2×+1.4×

Profitability

See full

Gross margin61.9%-3.1pp

Operating margin-46%+9.9pp

Net margin-16.2%-6.2pp

FCF margin-16.1%-4.8pp

Returns & leverage

See full

Return on equity-77.8%-22.4pp

Debt / equity3.1×-0.6×

Current ratio5.8×+0.3×

Where this comes from

Reported directly by Apyx Medical Corporation in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Apyx Medical Corporation’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apyx Medical Corporation's surgical aesthetics — investment income interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Apyx Medical Corporation's surgical aesthetics — investment income interest?: Apyx Medical Corporation (APYX) reported surgical aesthetics — investment income interest of $0 in Q1 2026.
What does surgical aesthetics — investment income interest mean?: This metric reflects the interest income earned on cash or cash equivalents specifically allocated to or generated by the Surgical Aesthetics segment. It highlights the segment's ability to generate non-operating returns from its liquid assets.